ADPT — Adaptive Biotechnologies Share News
0.000.00%
Last trade - 00:00- $4.08bn
- $4.08bn
- $276.98m
Brief: Adaptive Biotechnologies Corp - Adaptive's Work With Epic Will Commence Immediately, With Clonoseq Integration Expected To Go Live In 2023
Brief: Adaptive Biotech Announces Non-Dilutive Royalty Financing With Orbimed For Up To $250 Mln
U.S. RESEARCH ROUNDUP- Analog Devices, Bath & Body Works, Synopsys
Brief: Adaptive Biotechnologies Reports Second Quarter 2022 Financial Results
Brief: Adaptive Biotechnologies Receives Expanded Medicare Coverage Of Clonoseq
Brief: Adaptive Biotechnologies Launches T-Detect Lyme, A New T-Cell Clinical Test For Detection Of Early Lyme Disease
U.S. RESEARCH ROUNDUP- Ansys, Century Communities, Mirati Therapeutics
Adaptive Biotechnologies Corp reports results for the quarter ended in March - Earnings Summary
Brief: Adaptive Biotechnologies Reports First Quarter 2022 Financial Results
Adaptive Biotechnologies Corp expected to post a loss of 45 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Nike, Ebix, Cano Health
Adaptive Bio leaps on reorganization plans, workforce reduction
Brief: Adaptive Biotechnologies Appoints Tycho Peterson As Chief Financial Officer, Reorganizes And Streamlines Workforce
U.S. RESEARCH ROUNDUP-Advance Auto Parts, Airbnb, Marriott
Adaptive Biotechnologies Corp reports results for the quarter ended in December - Earnings Summary
Brief: Adaptive Biotechnologies Reports Fourth Quarter And Full Year 2021 Financial Results
U.S. RESEARCH ROUNDUP-Akumin, Electric last Mile Solutions, PayPal Holdings
Brief: Adaptive Biotechnologies Sees FY 2021 Revenue $153 Mln To $154 Mln
Brief: Adaptive Biotechnologies Announces New Data Demonstrating The Benefit Of Serial Mrd Testing With The Clonoseq® Assay In Patients With Blood Cancers At The 63Rd Ash Annual Meeting